CINCINNATI, Jan. 23, 2020 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of a High-Specificity Pfu HS Mix that not only provides high-fidelity amplification, but also offers market-leading amplification for companion diagnostic (CDx) and clinical testing.

High-fidelity amplification is essential for applications whose outcome depends upon the correct DNA sequence, such as next generation sequencing (NGS), cloning, and genotyping. However, results from such amplifications can be compromised by a DNA polymerase incapable of evenly amplifying diverse types of sequences or if samples contain inhibitors.

The Life Science Division of Meridian Bioscience has addressed these challenges by developing High-Specificity Pfu HS Mix as a high-fidelity amplification solution, with market leading properties in terms of inhibitor resistance, multiplexing and low GC bias. It is a perfect tool for NGS technologies applied to the clinical market, especially in the field of genetic testing and cancer screening, i.e., the development of panels for tumor or mutation profiling.

Lourdes Weltzien, Ph.D., Executive Vice President of Life Science, commented, “High-fidelity polymerases have been susceptible to difficulties in PCR amplification of GC-rich or inhibitor-rich DNA. High-Specificity Pfu HS Mix has dramatically reduced these limitations and will increase customers’ testing capabilities.”

“In NGS-based clinical assays, being able to sequence all the DNA regions of the sample independently from GC-content is essential. Using our extensive expertise in enzymes and buffer systems, High-Specificity Pfu HS Mix has been designed to achieve this. From target enrichment to library amplification, it allows better NGS data and more accurate results,” says Florent Chang-Pi-Hin, Ph.D., Senior Director, Research & Development at Meridian.

About Meridian Bioscience, Inc.

Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications. Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing.  We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.

Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is

Jack Kenny
Chief Executive Officer
Meridian Bioscience, Inc.
Phone:  513.271.3700